Drug name - Onzetra Xsail
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8047202 | CURRAX | Nasal devices |
Jul, 2023
(9 months from now) | |
| US8327844 | CURRAX | Nasal delivery method |
Oct, 2023
(1 year, 5 days from now) | |
| US9119932 | CURRAX | Nasal delivery device |
Apr, 2024
(1 year, 6 months from now) | |
| US7975690 | CURRAX | Nasal devices |
Aug, 2025
(2 years from now) | |
| US8590530 | CURRAX | Nasal delivery devices |
Sep, 2025
(2 years from now) | |
| US9108015 | CURRAX | Nasal delivery devices |
Sep, 2025
(2 years from now) | |
| US10124132 | CURRAX | Nasal delivery |
Mar, 2027
(4 years from now) | |
| US10398859 | CURRAX | Nasal delivery devices |
Dec, 2027
(5 years from now) | |
| US8875704 | CURRAX | Nasal administration |
Apr, 2028
(5 years from now) | |
| US10722667 | CURRAX | Nasal administration |
Dec, 2028
(6 years from now) | |
| US10076615 | CURRAX | Nasal delivery |
Jul, 2029
(6 years from now) | |
| US8550073 | CURRAX | Nasal delivery |
Oct, 2029
(7 years from now) | |
| US8899229 | CURRAX | Powder delivery devices |
Aug, 2030
(7 years from now) | |
| US9649456 | CURRAX | Nasal administration |
Oct, 2030
(8 years from now) | |
| US8978647 | CURRAX | Nasal delivery |
Dec, 2030
(8 years from now) | |
| US10478574 | CURRAX | Nasal administration |
Nov, 2033
(11 years from now) | |
| US10076614 | CURRAX | Nasal delivery devices |
Oct, 2034
(12 years from now) | |
Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient
Treatment: Method of drug delivery via the nasal cavity; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity; Acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Method of delivering sumatriptan to a nasal cavity
Dosage: POWDER;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 11MG BASE | POWDER;NASAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.